Product: Cefepime hydrochloride Non-sterile Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable. The material is a semisynthetic fourth-generation cephalosporin antibiotic supplied as the hydrochloride salt, CAS 123171-59-5, with molecular formula C₁₉H₂₅ClN₆O₅S₂ and molecular weight 517.02 g/mol for the anhydrous form. The non-sterile pharmaceutical grade is produced under ICH Q7 GMP conditions and is assigned for further processing into sterile injectable presentations by aseptic filtration and into tablet, capsule, or granule intermediates where intended use and stability data support the selected route.

The anhydrous hydrochloride contains 92.95% cefepime base by weight; therefore, 1.075 g of anhydrous cefepime hydrochloride is required to provide 1.000 g of cefepime base. Potency calculations for batch charging must correct for the actual water content determined by Karl Fischer titration. The powder appears as a white to pale yellow crystalline solid and is hygroscopic; prolonged exposure to relative humidity above 60% can increase water content and alter flow if the material is held open. Containers should be reclosed immediately after sampling, and warehouse temperature should be maintained at 20–25°C. The retest interval is assigned from long-term and accelerated stability data according to ICH Q1A.

Cefepime contains the 2-aminothiazolyl oxime side chain and a quaternary N-methylpyrrolidinium substituent, giving the molecule zwitterionic character. This structure permits rapid penetration through the outer membrane porins of Gram-negative bacilli and reduces affinity for inducible chromosomal AmpC β-lactamases. The API inhibits penicillin-binding proteins PBP_1A, PBP_1B, PBP₂, and PBP₃ in susceptible organisms. The non-sterile material is not intended for direct administration; it is an input to further formulation, filtration, and aseptic processing.

What compendial specifications govern the non-sterile API for oral and injectable conversion?

Release testing follows the current United States Pharmacopeia and European Pharmacopoeia monographs for cefepime hydrochloride. The certificate of analysis includes identification, assay, related substances, water content, residual solvents, and—when the batch is intended for injectable conversion—bacterial endotoxin and bioburden results. Table 1 lists the analytical panel and reference methods; exact acceptance limits are batch- and monograph-specific.

Because the API is non-sterile, injectable conversion requires validation of the sterile filtration process per ICH Q9 and PDA Technical Report No. 26. The bacterial endotoxin limit in Table 1 is calculated from the K/M ratio in USP <85>; each downstream manufacturer must recalculate the limit based on the highest single dose and patient population.

When tablet and capsule blending requires control of cohesive powder flow

In solid oral processing, cefepime hydrochloride may show cohesive flow and segregation if the received particle size distribution is broad. Bulk and tapped density values measured by USP <616> are used to calculate the Carr index and Hausner ratio; a Hausner ratio above 1.35 generally indicates the need for dry granulation or slugging before capsule filling or tablet compression. The API can be dry-blended with microcrystalline cellulose and croscarmellose sodium in low-shear tumble mixers at 15–25 rpm for 15–30 min; endpoint is determined by blend uniformity acceptance criteria, typically ≤5.0% RSD for the active fraction. Roller compaction with a side-sealed roll press at roll pressure 20–40 kN has been applied to densify the blend; published data for cefepime hydrochloride in this specific configuration is limited, so the ranges must be confirmed with the actual formulation.

Wet granulation is constrained by hydrolytic degradation of the β-lactam ring. If aqueous granulating fluid is used, the granule drying step should be performed with inlet air temperature not exceeding 45°C and residual moisture controlled to prevent ring hydrolysis. The main degradation products—open-ring and related substances—are monitored by the HPLC procedure in the monograph. Dry granulation is preferred for tablets and capsules because it avoids the hydrolytic stress of water-based binders.

Encapsulation of the milled or granulated material can be performed on dosator or tamping-pin capsule machines. Weight variation and content uniformity are evaluated per USP <905> and dissolution per USP <711>; however, no official dissolution test for oral cefepime hydrochloride tablets or capsules exists. Development laboratories typically use USP Apparatus 2 at 50 rpm in 0.1 M HCl or water, but this method must be validated against in vivo relevance because the drug is poorly absorbed.

For granule presentations, the non-sterile API can be dry-mixed with sucrose, mannitol, or lactose and filled into sachets after sieving through a 0.5 mm screen. The oral route is not typical for cefepime, however, because the quaternary nitrogen and carboxylate moieties limit passive intestinal permeability. Systemic absorption from oral cefepime hydrochloride is insufficient for treatment of systemic infections in humans; published human bioavailability data for oral cefepime HCl is limited. Therefore, oral tablets, capsules, and granules containing cefepime hydrochloride should be developed only for local gastrointestinal indications or as investigational formulations, not as substitutes for injectable therapy.

The Oral Bioavailability Barrier in Cefepime Hydrochloride

The zwitterionic structure of cefepime hydrochloride—the permanent positive charge on the N-methylpyrrolidinium ring and the carboxylate at the cephalosporin C-2 position—creates low lipid solubility and poor passive diffusion across the intestinal epithelium. Unlike cefalexin, which is absorbed by the intestinal peptide transporter PEPT1, or cefuroxime axetil and cefixime, which are dosed as ester prodrugs or absorbed after carrier-mediated transport, cefepime lacks an orally bioavailable prodrug moiety. The absence of an ester at the C-2 carboxylate limits the oral fraction absorbed; hence injectable administration remains the pharmacologically relevant route. In comparative susceptibility testing, cefepime is active against many Enterobacterales, Pseudomonas aeruginosa, and methicillin-susceptible Staphylococcus aureus; these infections require systemic exposure that cannot be achieved by oral dosing of the hydrochloride salt.

For injectable manufacturing, the non-sterile cefepime hydrochloride is dissolved in Water for Injection at typical concentrations of 100 mg/mL cefepime equivalents; L-arginine is added to adjust the final pH to 4.0–6.0 after reconstitution. The solution is prefiltered through a 0.45 µm membrane and then sterilized through a 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride filter. Filter validation requires product-specific bacterial retention studies using Brevundimonas diminuta per ASTM F838-20 and extractables/leachables evaluation per ISO 10993-1. Terminal steam sterilization is generally unsuitable because the β-lactam ring hydrolyzes at elevated temperature; aseptic filtration and lyophilization preserve the potency.

Injectable Manufacturing Route and Sterile-Filtration Compatibility

Endotoxin control begins in synthesis and purification rather than after the API is dried. Dry-heat depyrogenation is not applied to cefepime hydrochloride because it can cause degradation, so water, solvents, filter aids, and drying equipment must be controlled. The bacterial endotoxin limit for injectable API is calculated from the maximum clinical dose; for a 2 g dose and 70 kg patient, the limit is 0.175 EU/mg. If the maximum daily dose is 6 g, the limit is 0.058 EU/mg. Manufacturers using the non-sterile API for injectable presentations should verify that the supplied certificate of analysis contains LAL results and that water content is within the hydrate-appropriate range before formulation.

Differences from Ceftazidime and Cefotaxime in Clinical and Manufacturing Use

Cefepime hydrochloride differs from selected third-generation cephalosporins in outer-membrane penetration, β-lactamase stability, and Gram-positive coverage. The quaternary ammonium charge accelerates penetration through OmpF and OmpC porins in Gram-negative bacilli, while the low affinity for AmpC β-lactamases permits activity against many derepressed Enterobacterales. Ceftazidime retains strong Pseudomonas aeruginosa coverage but is often hydrolyzed by AmpC β-lactamases and has weak Gram-positive activity; cefotaxime has moderate Gram-positive activity but weak Pseudomonas coverage and is also AmpC-unstable. Table 2 summarizes the comparative profile.

Compared with ceftazidime pentahydrate, cefepime hydrochloride has a higher base content per gram: 92.95% versus 85.84% for ceftazidime pentahydrate. This difference directly affects the salt charge required to deliver the labeled cefepime amount in injectable admixture manufacture and in batch potency calculations. Each receiving site should execute a supplier quality agreement that defines particle size, residual solvent, and elemental impurity data exchange. Elemental impurities are controlled per ICH Q3D; risk assessment for the 24 elements with parenteral and oral permitted daily exposure categories is required. The non-sterile grade is not interchangeable with a sterile-grade API; downstream sites must maintain the validated aseptic processing steps and endotoxin barriers appropriate to the target dosage form.